Predicting human developmental toxicity of pharmaceuticals using human stem-like cells and metabolomics
US8703424B2 · kind B2 · utility
4Cited by
5References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 22, 2011 |
| Grant date | Apr 22, 2014 |
| Priority date | — |
| Expiry date | Jun 6, 2031 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N33/6848
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The invention provides biomarker profiles of metabolites and methods for screening chemical compounds including pharmaceutical agents, lead and candidate drug compounds and other chemicals using human stem-like cells (hSLCs) or lineage-specific cells produced therefrom. The inventive methods are useful for testing toxicity, particularly developmental toxicity and detecting teratogenic effects of such chemical compounds. Specifically, a more predictive developmental toxicity model, based on an in vitro method that utilizes both hSLCs and metabolomics to discover biomarkers of developmental toxicity is disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.